Fust, Kelly
Maschio, Michael
Kohli, Michele
Singh, Simron
Pritchard, D. Mark
Marteau, Florence
Myrenfors, Peter
Feuilly, Marion
Funding for this research was provided by:
Ipsen Pharma
Article History
First Online: 11 March 2020
Compliance with Ethical Standards
:
: Medical writing and editorial support was funded by Ipsen Pharma (Boulogne-Billancourt, France) in accordance with good publication practice guidelines. This study and model development was sponsored by Ipsen Pharma (Boulogne-Billancourt, France).
: KF is employed by Optum. MM and MK were formerly employed by Optum. SS has received honoraria from Ipsen Pharma and Novartis, and research funding/fellowship support from Ipsen Pharma, Novartis, Merck EMD Serono and Pfizer. DMP has received honoraria from Advanced Accelerator Applications (AAA) and Ipsen Pharma, and research funding from Trio Medicines Ltd. FM, PM, MF are employed by Ipsen Pharma.
: Where patient data can be anonymised, Ipsen will share all individual participant data that underlie the results reported in this article with qualified researchers who provide a valid research question. Study documents, such as the study protocol and clinical study report, are not always available. Proposals should be submitted to DataSharing@Ipsen.com and will be assessed by a scientific review board. Data are available beginning 6 months and ending 5 years after publication; after this time, only raw data may be available.
: KF, MM, MK, SS, DMP, FM and MF made substantial contributions to the study conception/design or acquisition/analysis/interpretation of the data. KF, MM, MK, SS, DMP, FM, PM and MF drafted the publication or revised it critically for important intellectual content. MM, MK, SS, DMP, FM, PM and MF approved the manuscript for publication.